 representing the most common form.){kind=link}
Lung cancer surgery market continues to be a global health challenge, with non-small cell lung cancer (NSCLC) representing the most common form. Surgery has traditionally been a primary treatment for early-stage disease. However, long-term survival remains a concern, as more than 50% of patients with stage 2 or 3 lung cancer experience relapse even after surgery. Recent developments in neoadjuvant immunotherapy using immune-based treatments before surgery are reshaping the landscape of lung cancer surgery, offering hope for significantly improved outcomes.
Why Is Neoadjuvant Immunotherapy Gaining Momentum in Lung Cancer Surgery?
The CheckMate 816 trial, a Phase III study led by Prof. Patrick Forde of Trinity St. James’s Cancer Institute, enrolled 358 patients worldwide with operable NSCLC. The trial investigated whether adding nivolumab, an immunotherapy drug, to standard chemotherapy prior to surgery could improve long-term survival.
Results from the trial demonstrated that patients receiving the combination therapy were approximately 10% more likely to be alive at five years than those receiving chemotherapy alone. Additionally, 24% of patients treated with immunotherapy plus chemotherapy had no remaining cancer at the time of surgery a result known as pathologic complete response. Notably, none of these patients died from lung cancer within five years. Side effects were not increased, and surgeries were performed successfully. These findings have led to the approval of neoadjuvant nivolumab plus chemotherapy as a standard treatment for eligible patients in multiple countries, including Ireland.
How Does Immunotherapy Improve Surgical Outcomes?
Immunotherapy enhances the body’s ability to fight cancer by blocking the PD-1 receptor, which helps the immune system recognize and attack tumors more effectively. Administering immunotherapy before surgery increases the likelihood of complete tumor elimination and reduces the risk of relapse.
Earlier studies led by Prof. Forde in 2018 already showed promising results, with nearly half of patients undergoing surgery after cancer immunotherapy showing minimal or no remaining cancer. The current CheckMate 816 findings confirm that combining immunotherapy with chemotherapy before surgery not only improves survival but also maintains a favorable safety profile.
What Are the Emerging Opportunities in the Lung Cancer Surgery Market?
Beyond the current chemo-immunotherapy protocols, emerging combination therapies are opening new possibilities in the lung cancer surgery market. The NeoCOAST-2 trial, conducted in Ireland, combined standard chemo-immunotherapy with a novel antibody-drug conjugate (ADC) prior to surgery. Patients receiving this combination were more likely to have no viable cancer remaining, suggesting that adding ADCs could further enhance outcomes.
These advancements are creating opportunities for hospitals to expand surgical and treatment offerings, while pharmaceutical companies developing immunotherapies and ADCs may see increased demand. Improved survival rates also encourage earlier interventions, which can boost the adoption of advanced surgical procedures.
What Are the Challenges and Considerations for Adoption?
Despite the clear benefits, several challenges must be addressed. Patient eligibility is critical, as not all individuals with NSCLC are suitable for neoadjuvant immunotherapy. The high cost of immunotherapy can also be a barrier, especially where insurance coverage is limited. Additionally, surgeons and oncologists require training to implement these new protocols effectively. Ongoing clinical trials remain essential to refine treatment combinations and validate long-term outcomes.
Next Steps – Actionable Takeaways for Stakeholders
To maximize the impact of neoadjuvant immunotherapy, stakeholders in the lung cancer surgery market can take several steps. Expanding access to clinical trials will allow more patients to benefit from cutting-edge treatments and accelerate the generation of survival data. Hospitals should integrate evidence-based immunotherapy protocols where approved, while clinicians must be trained to manage these combined treatments effectively.
- Expand Access to Clinical Trials: Encourage patient participation in neoadjuvant immunotherapy trials to accelerate data collection and improve survival outcomes.
- Integrate Evidence-Based Protocols: Hospitals should adopt chemo-immunotherapy protocols for eligible patients where approved.
- Train Clinicians: Surgeons and oncologists need specialized training to implement immunotherapy and combination therapies safely and effectively.
- Invest in Combination Therapies: Pharmaceutical companies should explore ADCs and other innovative treatments to enhance surgical outcomes.
- Monitor Long-Term Data: Continuously track survival rates and relapse statistics to refine treatment strategies and guide market forecasting.
Conclusion
The lung cancer surgery market in 2025 is being transformed by neoadjuvant immunotherapy. Clinical evidence from the CheckMate 816 and NeoCOAST-2 trials shows that combining immunotherapy with chemotherapy before surgery increases five-year survival rates by approximately 10%, achieves pathologic complete responses in a subset of patients, and reduces cancer relapse without adding significant surgical risk. These advancements improve patient outcomes while also driving market growth and creating new opportunities for hospitals, clinicians, and pharmaceutical companies. Strategic adoption of these therapies can establish a new standard of care and offer patients the best chance at long-term survival.
About the Author
Tania Dey is a content writer and SEO executive specializing in transformation-focused and insight-driven narratives. She develops compelling, research-backed content aligned with evolving business priorities, digital behavior, and audience expectations. Her work supports organizations in articulating clear value propositions, strengthening visibility, and communicating strategic intent effectively. Passionate about storytelling grounded in data, she emphasizes clarity, relevance, consistency, and measurable digital impact across platforms. She can be reached at: info@nextmsc.com